Back to Search Start Over

Patritumab Deruxtecan in Untreated Hormone Receptor–Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study